Undisclosed
Navigation Links
Undisclosed in Medical News
DOYLESTOWN, Pa., May 19 /PRNewswire-FirstCall/ -- The Quigley Corporation, (Nasdaq: QGLY ) , www.quigleyco.com , today announced that it has uncovered an improper financial relationship between Ted Karkus and the Company's Quigley Pharma, Inc. wholly-owned subsidiary COO, Dr. Richard A. ...
...xclusivity. Caraco will take over the commercialization and sale of several products from Forest's Inwood business. Caraco will pay Forest an undisclosed advance against royalties and royalties on net sales of these products. In exchange for an upfront payment (and royalties but only if the tech...
...ll address inflammatory and autoimmune diseases. Catalyst will receive undisclosed upfront licensing fees, full-time employee (FTE) support and milestone paym...preclinical development by Catalyst of Alterase(TM) therapeutics against an undisclosed target, with an option to expand the agreement to include a second target. ...
Coffee king American Flavor 3 in 1 Coffee mix contains undisclosed milk protein
Ottawa - The Canadian Food Inspection Agency (CFIA) has issued a warning for those who are allergic to milk, to avoid consumption of the Coffee king American Flavor// 3 in 1 Coffee mix brand. This product is said to contain a milk protein ingredient which the manufacturers have not disclosed on the...Allergy Alarm: Sam's Choice Milk Chocolate Turns Bitter with Undisclosed 'Nuts'
Brach's Confections, Inc. of Dallas, Texas are tough nuts to crack, indeed. Presently, they have withdrawn a batch of production of Sam's Choice Belgian Milk Chocolate Bars,// due to the presence of undeclared almonds. This is a precautionary measure to ensure safety for all those who are allergic ...Micromet, Inc. Reports Second Quarter 2009 Financial Results
...eement with Bayer Schering Pharma AG under which Bayer Schering Pharma was granted an exclusive option to license a specified BiTE antibody against an undisclosed solid tumor target. Other BiTE antibodies targeting MSCP, CD33, HER2, EGFR and other targets are in various stages of preclinical development. ...Ned Russell Joins Saatchi & Saatchi Wellness
...nth SSW was awarded the Durex account following a review. In addition, the agency has picked up four additional assignments in health and wellness for undisclosed new products. "Saatchi & Saatchi Wellness is an agency with a distinct point of view and focus - marketing well-being is a strong differ......xclusivity. Caraco will take over the commercialization and sale of several products from Forest's Inwood business. Caraco will pay Forest an undisclosed advance against royalties and royalties on net sales of these products. In exchange for an upfront payment (and royalties but only if the tech...
Health Club Media Network Acquires the Alloy Fitness Network
...ational brands in health clubs, announced today its acquisition of the Alloy Fitness Network from Alloy Media + Marketing. The transaction includes an undisclosed cash sum plus certain future contingent payments. The Alloy Fitness Network includes contractual agreements for media panel placements in over 70......ll address inflammatory and autoimmune diseases. Catalyst will receive undisclosed upfront licensing fees, full-time employee (FTE) support and milestone paym...preclinical development by Catalyst of Alterase(TM) therapeutics against an undisclosed target, with an option to expand the agreement to include a second target. ...
Crestor Patent Invalidity Evidence Uncovered By Article One Partners Community
...mmunity working to legitimize the validity of patents. Community members - whom Article One calls Advisors - have an opportunity to send in previously undisclosed evidence of patent validity. By tapping the unique knowledge and referral networks of our Advisors, this evidence known as prior art can be discovered...KV Pharmaceutical Forms Licensing Partnership with Gedeon Richter
...and distribute certain of KV's proprietary technologies and products in its territories, including the European Union. KV Pharmaceutical will receive undisclosed milestones and royalties for products developed under the terms of the agreement. The agreement also provides for the development of additional p...Undisclosed in Medical Technology
EUCODIS Bioscience Achieves Development Milestone in Second Collaboration With Lohmann Animal Health
...d marketing enzymes and other proteins for the chemical industry, announced today that it has achieved an important milestone in the development of an undisclosed protein for Lohmann Animal Health (LAH), a leading provider of feed components and vaccines for farm animals. This achievement triggered a milestone p......eement with Bayer Schering Pharma AG under which Bayer Schering Pharma was granted an exclusive option to license a specified BiTE antibody against an undisclosed solid tumor target. Micromet's preclinical product pipeline includes several novel BiTE antibodies generated with its proprietary BiTE antibody plat...
...eement with Bayer Schering Pharma AG under which Bayer Schering Pharma was granted an exclusive option to license a specified BiTE antibody against an undisclosed solid tumor target. Micromet's preclinical product pipeline includes several novel BiTE antibodies generated with its proprietary BiTE antibody plat...
...body and will thereafter assume responsibility for further clinical development and commercialisation on a worldwide basis. OBT will receive an undisclosed upfront payment and will be eligible for up to a total of $370m (GBP244m) upon the achievement of specified discovery, development, regulatory and com...
Micromet Presents Update on BiTE Antibody Pipeline and Reviews Key AACR Presentations at R&D Day
...rthritis, psoriasis, or multiple sclerosis. Micromet has granted an exclusive option to Bayer Schering Pharma AG to license a BiTE antibody against an undisclosed solid tumor target. Additional BiTE antibodies, targeting CEA, CD33, Her2, EGFR and MCSP, respectively, are in different stages of preclinical develop......rthritis, psoriasis, or multiple sclerosis. Micromet has granted an exclusive option to Bayer Schering Pharma AG to license a BiTE antibody against an undisclosed solid tumor target. Additional BiTE antibodies, targeting CEA, CD33, Her2, EGFR and MCSP, respectively, are in different stages of preclinical develop...
Micromet Receives Milestone Payment for Filing of the First Clinical Trial Application for MT203
... to be initiated in the first half of 2009. Micromet has granted an exclusive option to Bayer Schering Pharma AG to license a BiTE antibody against an undisclosed solid tumor target. Additional BiTE antibodies, targeting CEA, CD33, Her2, EGFR and MCSP, respectively, are in different stages of preclinical develop...Micromet Has Started a New Phase 2 Trial with Adecatumumab in Colorectal Cancer Patients
...rthritis, psoriasis, or multiple sclerosis. Micromet has granted an exclusive option to Bayer Schering Pharma AG to license a BiTE antibody against an undisclosed solid tumor target. Additional BiTE antibodies, targeting CEA, CD33, Her2, EGFR and MCSP, respectively, are in different stages of preclinical develop......dates TG-C and TG-B, developed for the regeneration of cartilage and bone, respectively. Under the terms of the agreement, TissueGene has received an undisclosed up-front payment and will receive on-going royalty payments based upon future sales. TissueGene is currently completing Phase I clinical trials in th...
...payment to Ambrx, and Ambrx is eligible to receive undisclosed clinical, regulatory and commercial milestone paym...ucts resulting from this collaboration, as well as undisclosed royalties on the associated worldwide net sales. A... as profit. In addition, Merck Serono will make an undisclosed equity investment in Ambrx. Additional terms of t...
Undisclosed in Biological News
Chantix side effects no worse with depression history
...e trial detected only one serious psychiatric event involving suicidal thoughts and requiring hospitalization. It was in a person who had a previously undisclosed history of bipolar disorder. ...Re-analysis of cigarettes confirms tobacco companies increased addictive nicotine 11 percent
... smoking each year. In conclusion, according to the HSPH researchers, the extended analysis of MDPH data has demonstrated its potential to reveal undisclosed hazards to human health. They suggest that MDPH amend its unique reporting requirements to include more information about cigarette and smokeless toba...Undisclosed in Biological Technology
LAUSANNE, Switzerland and BANGALORE, India, November 20 /PRNewswire/ --
Debiopharm Group (Debiopharm), a global biopharmaceutical development
specialist that focuses on serious medical conditions and particularly
oncology, and Aurigene Discovery Technologies Ltd (Aurigene), a
Bangalore-based fully...
...eement with Bayer Schering Pharma AG under which Bayer Schering Pharma was granted an exclusive option to license a specified BiTE antibody against an undisclosed solid tumor target. Other BiTE antibodies targeting MSCP, CD33, HER2, EGFR and other targets are in various stages of preclinical development. ...
...eement with Bayer Schering Pharma AG under which Bayer Schering Pharma was granted an exclusive option to license a specified BiTE antibody against an undisclosed solid tumor target. Other BiTE antibodies targeting MSCP, CD33, HER2, EGFR and other targets are in various stages of preclinical development. ...
...eement with Bayer Schering Pharma AG under which Bayer Schering Pharma was granted an exclusive option to license a specified BiTE antibody against an undisclosed solid tumor target. Micromet's preclinical product pipeline includes several novel BiTE antibodies generated with its proprietary BiTE antibody plat...
Micromet Closes $80.5 Million Public Offering of Common Stock
...chering Pharma AG under which Bayer Schering Pharma was granted an exclusive option until January 2010 to license a specified BiTE antibody against an undisclosed solid tumor target. Other BiTE antibodies targeting MSCP, CD33, HER2, EGFR and other targets are in various stages of preclinical development. ......eement with Bayer Schering Pharma AG under which Bayer Schering Pharma was granted an exclusive option to license a specified BiTE antibody against an undisclosed solid tumor target. Other BiTE antibodies targeting MSCP, CD33, HER2, EGFR and other targets are in various stages of preclinical development. ...
Micromet Announces Pricing of Public Offering of Common Stock
...chering Pharma AG under which Bayer Schering Pharma was granted an exclusive option until January 2010 to license a specified BiTE antibody against an undisclosed solid tumor target. Other BiTE antibodies targeting MSCP, CD33, HER2, EGFR and other targets are in various stages of preclinical development. ...Micromet Announces Public Offering of Common Stock
...chering Pharma AG under which Bayer Schering Pharma was granted an exclusive option until January 2010 to license a specified BiTE antibody against an undisclosed solid tumor target. Other BiTE antibodies targeting MSCP, CD33, HER2, EGFR and other targets are in various stages of preclinical development. ......eement with Bayer Schering Pharma AG under which Bayer Schering Pharma was granted an exclusive option to license a specified BiTE antibody against an undisclosed solid tumor target. Other BiTE antibodies targeting MSCP, CD33, HER2, EGFR and other targets are in various stages of preclinical development. ...
BioWa Announces License of POTELLIGENT(R) Technology to Merck KGaA
...nts Merck KGaA non-exclusive rights to research, develop and commercialize therapeutic antibodies generated through POTELLIGENT((R)) Technology for an undisclosed number of targets. In return, BioWa will receive upfront payments, and may receive development milestone payments and royalties on products. Other d...Micromet Added to Russell 3000 Index
...eement with Bayer Schering Pharma AG under which Bayer Schering Pharma was granted an exclusive option to license a specified BiTE antibody against an undisclosed solid tumor target. Other BiTE antibodies targeting MSCP, CD33, HER2, EGFR and other targets are in various stages of preclinical development. F...AFFiRiS AG: 1st Place in Venture Capital & Private Equity Awards for MIG Fonds and AFFiRiS
...seases that have so far seemed unsuitable for treatment by vaccination, but that represent markets worth billions. Vaccine candidates for four further undisclosed chronic diseases are currently being developed by AFFiRiS AG. Asked about the success story of AFFiRiS AG and the current award, Andreas Höfle......eement with Bayer Schering Pharma AG under which Bayer Schering Pharma was granted an exclusive option to license a specified BiTE antibody against an undisclosed solid tumor target. Micromet's preclinical product pipeline includes several novel BiTE antibodies generated with its proprietary BiTE antibody plat...
Other TagsCyclinCyclinOther Contentsbiologybiologybiologybiologybiologybiologybiologybiologybiologyproblemsproblemsproblemsproblemsproblemsproblemsproblemsproblemsproblemsproblemsvacuolevacuolevacuolezosterzostervaricellavaricellavesiclevesiclevesiclevesiclefeverfeverfeverfeverfeverfeverfeverfever
(Date:12/4/2009)... , PALO ALTO, Calif., Dec. 4 /PRNewswire-Fi...announced today that its Board of Directors has se...for February 11, 2010 with a record date of Decemb...e Plaza Cabana Hotel, 4290 El Camino Real, Palo Al...will be webcast by Thomson Financial and can be ac...
(Date:12/4/2009)..., NEW YORK, Dec. 4 Thousands of ...ffices nationwide today, to participate in a commu...nd advisory firm,s support for literacy with chari...flects our firm,s long history of volunteerism. In...n the spirit of caring to brighten the holidays fo...
(Date:12/4/2009)..., PEMBROKE, Bermuda, Dec. 4 /PRNewswire-Firs... Ltd (NYSE: AWH ) today announced that Scott Car... Jack Sennott, Executive Vice,President and Chief ...the 2009,Goldman Sachs U.S. Financial Services Con... Center in New York City on Tuesday, December 8, 2...
(Date:12/4/2009)..., SCOTTSDALE, Ariz., Dec. 4 Health...d, non-traded, real estate investment trust, annou...t to acquire a three building medical office portf...s, and Fort Wayne, Indiana for approximately $20,5... to the satisfaction of a number of conditions. ,...
(Date:12/4/2009)... , MADISON HEIGHTS, Mich., Dec. 4 /PRNewsw...ew Committee of BetterInvesting Magazine today a...bruary 2010 "Stock to Study" and C.R. Bard, Inc. ...Stock" for investors, informational and educationa... of growth opportunities involving its flagship dr...
Breaking Medicine News(10 mins):Health News:Varian Medical Systems Schedules Annual Stockholder Meeting in Palo Alto 2Health News:KPMG Employees Provide 'Holiday Bear Hugs' and Books in Firmwide Service Day for Children 2Health News:Allied World to Present at the 2009 Goldman Sachs U.S. Financial Services Conference 2Health News:Healthcare Trust of America, Inc. Executes Agreement to Acquire a 92,500 Square Foot Medical Office Portfolio Located in Texas and Indiana 2Health News:BetterInvesting Magazine Releases February Stock to Study and Undervalued Stock Choicesfor Investors' Informational and Educational Use 2[0] Varian Medical Systems Schedules Annual Stockholder Meeting in Palo Alto[0] KPMG Employees Provide 'Holiday Bear Hugs' and Books in Firmwide Service Day for Children[0] Allied World to Present at the 2009 Goldman Sachs U.S. Financial Services Conference[0] Healthcare Trust of America, Inc. Executes Agreement to Acquire a 92,500 Square Foot Medical Office Portfolio Located in Texas and Indiana[0] BetterInvesting Magazine Releases February Stock to Study and Undervalued Stock Choicesfor Investors' Informational and Educational Use
(Date:12/3/2009)...UE, N.M. Most scientists believe that staph infec...al each other to emit toxins. The signaling proces...ust be present to start the process. , But the J... very first stage of staph infection, when bacteri...s in a single cell and that this individual proces...
(Date:12/3/2009)...fish can undergo a personality change in warmer wa...ng that climate change may make some species more ...ung damselfish on Australia,s Great Barrier Reef h...re either consistently timid, or consistently bold...ore marked as water temperatures rise. , A sligh...
(Date:12/3/2009)...lers must be included in the design of the upcomin...manitarian crisis, according to a scientist at the...e , Dr Simon Lewis argues that at least 50% of the..., known as REDD (Reducing Emissions from Deforesta...ellers directly, and their property rights assured...
Breaking Biology News(10 mins):Stopping MRSA before it becomes dangerous is possible, Sandia/UNM researchers find 2Stopping MRSA before it becomes dangerous is possible, Sandia/UNM researchers find 3Fish with attitude: Some like it hot 2Forest deal at Copenhagen must avoid creating 'carbon refugees' 2Day Care May Not Shield Kids From Asthma Allergies 56605 1Day Care May Not Shield Kids From Asthma Allergies 56605 2Day Care May Not Shield Kids From Asthma Allergies 56605 3American Airlines Employees Raise 241 Million for American Cancer Society 56600 1American Airlines Employees Raise 241 Million for American Cancer Society 56600 2American Airlines Employees Raise 241 Million for American Cancer Society 56600 3YMCA Expands Pioneering Healthier Communities Initiative to Lead Healthy Change in Communities Nationwide 56595 1YMCA Expands Pioneering Healthier Communities Initiative to Lead Healthy Change in Communities Nationwide 56595 2YMCA Expands Pioneering Healthier Communities Initiative to Lead Healthy Change in Communities Nationwide 56595 3YMCA Expands Pioneering Healthier Communities Initiative to Lead Healthy Change in Communities Nationwide 56595 4YMCA Expands Pioneering Healthier Communities Initiative to Lead Healthy Change in Communities Nationwide 56595 5| Copyright © 2003-2009 Bio-Medicine. All rights reserved. ABOUT | CONTACT US | DISCLAIMER | PRIVACY POLICY | TERMS AND CONDITIONS |  |